S. aureus and coagulase-negative staphylococci are the most frequent bacteria responsible for PJI (prosthetic joint infection). The aim of this study is to describe the use of rifampicin.
Study Type
OBSERVATIONAL
Enrollment
79
the aim is to determine if the dose and the duration of rifampin influenced the prognosis
Hospices Civils de Lyon
Lyon, France
description of the use of rifampicin : rate of use
the aim is to determine how the use of rifampin influence the prognosis in staphylococcal acute post-operative prosthetic joint infection treated with DAIR
Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
rate of failure for treatment using rifampin
Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin
Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
rate of adverse event with rifampin
Description of adverses events leading to stop the rifampicin
Time frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.